Holdings
Palo Alto Investors LP
As of Sep 30, 2026, Palo Alto Investors LP reported 49 positions worth US$628M. Largest: PTC Therapeutics, Inc., Iovance Biotherapeutics, Inc. and Insmed Incorporated. What it bought and sold, with each filing.
Holdings
- Positions
- 49
- Value as reported
- US$628M
- Holdings as of
- Sep 30, 2026
- Last filed
- Nov 16, 2026
| Company | Shares | Value as reported | % of company | % of portfolio | Change | As of |
|---|---|---|---|---|---|---|
| PTC Therapeutics, Inc. NASDAQ:PTCT | 875K | US$56.7M | 8.4% | −43,497 | Sep 30, 2026 | |
| Iovance Biotherapeutics, Inc. NASDAQ:IOVA | 3.47M | US$51.4M | 0.75% | 7.7% | −1.82M | Sep 30, 2026 |
| Insmed Incorporated NASDAQ:INSM | 444K | US$50.6M | 0.20% | 7.5% | +29,665 | Sep 30, 2026 |
| ACADIA Pharmaceuticals Inc. NASDAQ:ACAD | 2.49M | US$50.1M | 1.4% | 7.5% | −378K | Sep 30, 2026 |
| BioMarin Pharmaceutical Inc. NASDAQ:BMRN | 642K | US$38.5M | 0.33% | 5.7% | −40,322 | Sep 30, 2026 |
| Mirum Pharmaceuticals, Inc. NASDAQ:MIRM | 387K | US$33.1M | 4.9% | +38,506 | Sep 30, 2026 | |
| United Therapeutics Corporation NASDAQ:UTHR | 58,875 | US$31.9M | 4.7% | −3,712 | Sep 30, 2026 | |
| Dyne Therapeutics, Inc. NASDAQ:DYN | 1.88M | US$30.3M | 4.5% | +234K | Sep 30, 2026 | |
| Biogen Inc. NASDAQ:BIIB | 133K | US$30M | 0.09% | 4.5% | −7,361 | Sep 30, 2026 |
| AnaptysBio, Inc. NASDAQ:ANAB | 595K | US$29.9M | 4.5% | −8,225 | Sep 30, 2026 | |
| CareDx, Inc. NASDAQ:CDNA | 425K | US$27.6M | 0.81% | 4.1% | −107K | Sep 30, 2026 |
| First Tracks Biotherapeutics, Inc. NASDAQ:TRAX | 741K | US$26.3M | 1.8% | 3.9% | +138K | Sep 30, 2026 |
| Disc Medicine, Inc. NASDAQ:IRON | 397K | US$26M | 0.87% | 3.9% | −20,117 | Sep 30, 2026 |
| Bicara Therapeutics Inc. NASDAQ:BCAX | 689K | US$12.8M | 1.9% | +139K | Sep 30, 2026 | |
| Annexon, Inc. NASDAQ:ANNX | 2.81M | US$11.9M | 1.8% | −137K | Sep 30, 2026 | |
| Syndax Pharmaceuticals, Inc. NASDAQ:SNDX | 596K | US$11.2M | 1.7% | −269K | Sep 30, 2026 | |
| Celldex Therapeutics, Inc. NASDAQ:CLDX | 343K | US$11.1M | 1.7% | −56,755 | Sep 30, 2026 | |
| Ultragenyx Pharmaceutical Inc. NASDAQ:RARE | 710K | US$10.7M | 1.6% | +114K | Sep 30, 2026 | |
| Travere Therapeutics, Inc. NASDAQ:TVTX | 159K | US$9.36M | 1.4% | −8,579 | Sep 30, 2026 | |
| Compass Therapeutics, Inc. NASDAQ:CMPX | 7.15M | US$7.43M | 4.0% | 1.1% | +1.32M | Sep 30, 2026 |
| Agios Pharmaceuticals, Inc. NASDAQ:AGIO | 201K | US$6.68M | 0.99% | −12,617 | Sep 30, 2026 | |
| Taysha Gene Therapies, Inc. NASDAQ:TSHA | 1.34M | US$6.51M | 0.41% | 0.97% | −54,165 | Sep 30, 2026 |
| Aclaris Therapeutics, Inc. NASDAQ:ACRS | 1.16M | US$6.08M | 0.73% | 0.90% | −457K | Sep 30, 2026 |
| Capricor Therapeutics, Inc. NASDAQ:CAPR | 548K | US$5.19M | 0.94% | 0.77% | +318K | Sep 30, 2026 |
| Align Technology, Inc. NASDAQ:ALGN | 31,389 | US$4.56M | 0.68% | No change | Sep 30, 2026 | |
| Protara Therapeutics, Inc. NASDAQ:TARA | 1.04M | US$3.16M | 1.7% | 0.47% | New | Sep 30, 2026 |
| Contineum Therapeutics, Inc. NASDAQ:CTNM | 220K | US$2.96M | 0.44% | New | Sep 30, 2026 | |
| Edwards Lifesciences Corporation NYSE:EW | 33,640 | US$2.9M | <0.01% | 0.43% | No change | Sep 30, 2026 |
| Verastem, Inc. NASDAQ:VSTM | 325K | US$2.62M | 0.26% | 0.39% | +15,795 | Sep 30, 2026 |
| Neurocrine Biosciences, Inc. NASDAQ:NBIX | 18,117 | US$2.57M | 0.38% | No change | Sep 30, 2026 | |
| Sagimet Biosciences Inc. - Series A NASDAQ:SGMT | 250K | US$2.47M | 0.36% | 0.37% | No change | Sep 30, 2026 |
| Adlai Nortye Group Ltd. NASDAQ:ANL | 149K | US$2.39M | 0.25% | 0.36% | New | Sep 30, 2026 |
| Stoke Therapeutics, Inc. NASDAQ:STOK | 84,631 | US$2.2M | 0.33% | No change | Sep 30, 2026 | |
| Oruka Therapeutics, Inc. NASDAQ:ORKA | 25,563 | US$2.13M | 0.32% | −7,983 | Sep 30, 2026 | |
| Pyxis Oncology, Inc. NASDAQ:PYXS | 864K | US$2.01M | 0.72% | 0.30% | No change | Sep 30, 2026 |
| Cytokinetics, Incorporated NASDAQ:CYTK | 30,036 | US$1.98M | 0.29% | −2,159 | Sep 30, 2026 | |
| BioNTech SE NASDAQ:BNTX | 19,614 | US$1.93M | <0.01% | 0.29% | New | Sep 30, 2026 |
| Nuvation Bio Inc. NYSE:NUVB | 327K | US$1.83M | 0.09% | 0.27% | No change | Sep 30, 2026 |
| Xenon Pharmaceuticals Inc. NASDAQ:XENE | 47,902 | US$1.78M | 0.27% | −3,443 | Sep 30, 2026 | |
| Humana Inc. NYSE:HUM | 3,985 | US$1.52M | <0.01% | 0.23% | No change | Sep 30, 2026 |
| COMPASS Pathways Plc NASDAQ:CMPS | 116K | US$1.44M | 0.08% | 0.21% | New | Sep 30, 2026 |
| eHealth, Inc. NASDAQ:EHTH | 1.43M | US$1.02M | 4.4% | 0.15% | −51,262 | Sep 30, 2026 |
| Xeris Biopharma Holdings, Inc. NASDAQ:XERS | 104K | US$998K | 0.06% | 0.15% | No change | Sep 30, 2026 |
| Madrigal Pharmaceuticals, Inc. NASDAQ:MDGL | 1,787 | US$901K | <0.01% | 0.13% | No change | Sep 30, 2026 |
| Cybin, Inc. NEO:HELP | 72,634 | US$893K | 0.10% | 0.13% | New | Sep 30, 2026 |
| Bicycle Therapeutics PLC NASDAQ:BCYC | 188K | US$693K | 0.37% | 0.10% | New | Sep 30, 2026 |
| Inspire Medical Systems, Inc. NYSE:INSP | 8,772 | US$608K | 0.09% | No change | Sep 30, 2026 | |
| Abeona Therapeutics Inc. NASDAQ:ABEO | 109K | US$572K | 0.19% | 0.09% | No change | Sep 30, 2026 |
| Aldeyra Therapeutics, Inc. NASDAQ:ALDX | 156K | US$192K | 0.26% | 0.03% | No change | Sep 30, 2026 |